All News Hinova Pharmaceuticals Inc.

Equities

688302

CNE1000059F5

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
25.32 ^CNY	-6.40%		-10.59%	-51.37%

06-24	Hinova Pharmaceuticals Inc.(XSSC:688302) dropped from S&P Global BMI Index	CI
04-26	Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hinova Pharmaceuticals Inc.(XSSC:688302) dropped from S&P Global BMI Index	06-23	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
China Stocks Fall Ahead of March Economic Data Release	04-08	MT
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%	04-08	MT
China Healthcare Stocks Rally on Hopes for Government Support	03-14	DJ
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Hinova Pharmaceuticals Gets Nod to Trial HP537 Tablets	02-23	MT
Hinova Pharmaceuticals Gets US FDA's Nod to Conduct Phase II Clinical Trial on HP501 Tablets	12-07	MT
Hinova Pharmaceuticals Gets Nod to Test Prostate Cancer Drug	11-03	MT
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hinova Pharmaceuticals to Resubmit Application for Deuterated Enzalutamide Soft Capsules	23-10-23	MT
Hinova Pharmaceuticals Inc.(XSSC:688302) added to S&P Global BMI Index	23-09-17	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange Composite Index	23-04-13	CI
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange A Share Index	23-04-13	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Hinova Pharma Gets Regulatory Nod for Anti-Tumor Drug Trial	23-02-10	MT
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment	23-02-06	CI
Hinova Pharmaceuticals Gets FDA's Nod to Hold Trial on Anti-Cancer Drug; Shares Jump 5%	23-02-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Hinova Pharmaceuticals Inc.

Equities

688302

CNE1000059F5

All News

Filters